The importance of microalbuminuria as a cardiovascular risk indicator: A review

Canadian Journal of Cardiology

Volumn 18, Issue 5, 2002, Pages 525-535

  Diercks, G F H ^a   Van Boven, A J ^a   Hillege, J L ^a   De Jong, P E ^a   Rouleau, J L ^a   Van Gilst, W H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Epidemiology; Microalbuminuria; Prevention; Prognosis; Risk factors

Indexed keywords

ALBUMIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE;

ATHEROGENESIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE MARKER; HUMAN; HYPERTENSION; MICROALBUMINURIA; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; URINALYSIS; URINARY EXCRETION; URINE LEVEL; VASCULAR ENDOTHELIUM;

ALBUMINURIA; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; URINALYSIS;

EID: 0036062301     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus
2. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
3. Incipient nephropathy in Type 1 (insulin-dependent) diabetes
4. Prevention of diabetic renal disease with special reference to microalbuminuria
5. Microalbuminuria as predictor of increased mortality in elderly people
6. Urinary albumin excretion. An independent predictor of ischemic heart disease
7. Albuminuria vs. urinary total protein for detecting chronic renal disorders
8. An immunoassay method for urinary albumin at low concentration
9. Immunoassays for low concentrations of albumin in urine
10. Laser immunonephelometry for routine quantification of urinary albumin excretion
11. Microalbuminuria in diabetes mellitus: Review and recommendations for the measurement of albumin in the urine
12. Micral-test strips evaluated for screening for albuminuria
13. Non-diabetic microalbuminuria in clinical practice and its relationship to posture, exercise and blood pressure
14. Circadian rhythms and the kidney
15. Comparison of overnight, morning and 24-hour urine collections in the assessment of diabetic microalbuminuria
16. Microalbuminuria in elderly hyperglycaemic patients and controls
17. Microalbuminuria as a predictor of clinical diabetic nephropathy
18. Selecting the optimum specimen for assessing slight albuminuria and a strategy for clinical investigation: Novel use of data on biological evaluation
19. Screening for microalbuminuria: Which measurement
20. Predicting diabetic nephropathy in insulin-dependent patients
21. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals
22. Microalbuminuria and essential hypertension: Renal and cardiovascular implications
23. Microalbuminuria: Associations with height and sex in non-diabetic subjects
24. Epidemiology of microalbuminuria in the general population
25. Racial differences in the prevalence of microalbuminuria in hypertension
26. Microalbuminuria is not rare before 5 years of IDDM. EURODIAB IDDM Complications Study Group and the WHO Multinational Study of Vascular Disease in Diabetes Study Group
27. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension
28. Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs
29. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners
30. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension
31. Atherosclerosis profile and microalbuminuria in essential hypertension
32. Microalbuminuria in never-treated hypertensives: Lack of relationship to hyperinsulinemia and genetic predisposition to hypertension
33. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study)
34. Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications
35. Microalbuminuria in nondiabetic adults: Relation of blood pressure, body mass index, plasma cholesterol levels, and smoking. The Gubbio Population Study
36. Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects. The Copenhagen City Heart Study Group
37. Microalbuminuria and associated cardiovascular risk factors in the community
38. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey
39. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators
40. Microalbuminuria, is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
41. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion
42. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients
43. Microalbuminuria predicts mortality in non-insulin-dependent diabetics
44. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis
45. Morbidity, mortality, and albuminuria in type 2 diabetic patients: A three-year prospective study of a random cohort in general practice
46. Prospective study of microalbuminuria as predictor of mortality in NIDDM
47. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM
48. Albumin excretion and vascular deaths in NIDDM
49. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes: An eight-year follow-up study
50. Albuminuria and poor glycemic control predict mortality in NIDDM
51. Microalbuminuria in type 2 diabetes: An independent predictor of cardiovascular mortality
52. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature
53. Epidemiology of renal involvement in type II diabetics (NIDDM) in Catalonia. The Catalan Diabetic Nephropathy Study Group
54. Clinical and metabolic characteristics of type 1 and type 2 diabetes: An epidemiological study from the Narpes community in western Finland
55. Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus
56. Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area
57. Clinical factors associated with urinary albumin excretion in type II diabetes
58. Albuminuria and associated medical risk factors: A cross-sectional study in 476 type I (insulin-dependent) diabetic patients. Part 1
59. Albuminuria and associated medical risk factors: A cross-sectional study in 451 type II (noninsulin-dependent) diabetic patients. Part 2
60. Microalbuminuria and its associated risk factors in a representative sample of Italian type II diabetics
61. Microalbuminuria and other cardiovascular risk factors in nondiabetic subjects
62. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects?
63. Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension
64. Ambulatory blood pressure and microalbuminuria in essential hypertension: Role of circadian variability
65. Diurnal variations of blood pressure and microalbuminuria in essential hypertension
66. Relationship between level of blood pressure measured casually and severity of complications in essential hypertension
67. The prognostic value of ambulatory blood pressure
68. Ambulatory blood pressure: An independent predictor of prognosis in essential hypertension
69. Loss of the nocturnal decline in blood pressure in subjects with essential hypertension and microalbuminuria
70. Urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus
71. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients
72. Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: Role of insulin
73. Associations of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
74. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men
75. Pulse pressure and isolated systolic hypertension: Association with microalbuminuria. The Gubbio Study Collaborative Research Group
76. White-coat hypertension and cardiovascular risk
77. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study
78. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study
79. Microalbuminuria in essential hypertension
80. Microalbuminuria and endothelial dysfunction in essential hypertension
81. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons
82. Albuminuria in normals and essential hypertension
83. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study
84. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension
85. Insulin, sodium-lithium countertransport, and microalbuminuria in hypertensive patients
86. Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. Risk Factor Intervention Study Group
87. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria
88. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM
89. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms
90. Insulin resistance in essential hypertension
91. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus
92. Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria
93. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria
94. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease
95. Microalbuminuria precedes the development of NIDDM
96. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients
97. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study
98. Plasma homocysteine levels and mortality in patients with coronary artery disease
99. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
100. Free radical metabolites of L-cysteine oxidation
101. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
102. Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension
103. Relationship between cardiac hypertrophy and microabuminuria
104. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients
105. Micro-albuminuria as a predictor of cardiovascular damage in essential hypertension
106. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
107. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study
108. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals
109. Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals
110. Microalbuminuria as a predictive factor for cardiovascular events
111. Microalbuminuria is independently associated with ischaemic electrocardiographi abnormalities in a large nondiabetic population
112. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria
113. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS)
114. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
115. Proteinuria as a prognostic factor during long term hypertensive care
116. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension
117. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study
118. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Risk Factor Intervention Study Group
119. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease
120. Microalbuminuria in primary hypertension: Is it a marker of glomerular damage?
121. Microalbuminuria in diabetes mellitus: Review and recommendatiions for the measurement of albumin in urine
122. Increased urinary albumin-excretion rate in benign essential hypertension
123. Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia
124. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: The Hoorn Study
125. Microalbuminuria in never-treated hypertensives: Lack of relationship to hyperinsulinemia and genetic predisposition to hypertension
126. Insulin sensitivity in clinically healthy individuals with microalbuminuria
127. Microalbuminuria and renal haemodynamics in essential hypertension
128. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension
129. Albuminuria reflects widespread vascular damage. The Steno hypothesis
130. The pathogenesis of atherosclerosis: A perspective for the 1990s
131. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
132. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
133. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients
134. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria
135. Transcapillary escape rate of albumin and plasma volume in essential hypertension
136. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects
137. Renal and systemic transvascular albumin leakage in severe atherosclerosis
138. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria
139. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: Blunted vasoconstriction in patients with microalbuminuria
140. Endothelial dysfunction of conduit arteries in insulin-dependent diabetes mellitus without microalbuminuria
141. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes
142. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent mellitus
143. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria
144. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria
145. Features of endothelial dysfunction in early diabetic nephropathy
146. Macromicroangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy
147. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: A 4-year prospective study
148. Endothelial dysfunction precedes development of microalbuminuria in IDDM
149. Coronary heart disease in diabetes mellitus: Three new risk factors and a unifying hypothesis
150. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease
151. Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria
152. Lipid disorders and diabetes
153. Lipoprotein lipase
154. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes
155. Effects of p-nitorphenyl-beta-D-xyloside on proteoglycan synthesis and extracellular matrix formation by bovine corneal endothelial cell cultures
156. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus
157. Is microalbuminuria in diabetes due to changes in glomerular heparan sulphate?
158. Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane
159. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy
160. Extracellular matrix in human diabetic nephropathy: Reduced expression of heparan sulphate in skin basement membrane
161. Characterization of heparan sulfate-proteoglycan of glomerular basement membranes
162. Anionic sites and mechanisms of proteinuria
163. A monoclonal antibody against GDM heparan sulphate induces an acute selective proteinuria in rats
164. Size- and charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria
165. Evidence of impaired glomerular charge selectivity in nondiabetic subjects with microalbuminuria: Relevance to cardiovascular disease
166. Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria
167. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells
168. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth
169. Structure and affinity for antithrombin of heparan sulfate chains derived from basement membrane proteoglycans
170. Glycosaminoglycan in normal and atherosclerotic human coronary arteries
171. Diabetic macroangiopathy. Quantitative histopathological studies of the extramural coronary arteries from type 2 (non-insulin-dependent) diabetic patients
172. Involvement of cell surface heparin sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells
173. Pathogenesis of diabetic vascular disease: Evidence for the role of reduced heparan sulfate proteoglycan
174. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients
175. Microalbuminuria and transcapillary albumin leakage in essential hypertension
176. Albumin excretion rate is not increased in atherosclerotic patients with peripheral vascular disease
177. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria
178. Heterogeneous nature of microalbuminuria in NIDDM: Studies of endothelial function and renal structure
179. How heterogeneous is microalbuminuria in diabetes mellitus? The case for 'benign' and 'malignant' microalbuminuria
180. Prevention of diabetic nephropathy in db/db mice with gylcated albumin antagonists. A novel treatment strategy
181. Advanced glycation end products in serum predicts changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
182. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study
183. Early recognition of autonomic dysfunction in microalbuminuria: Significance for cardiovascular mortality in diabetes mellitus?
184. Epidemiology of microalbuminuria in a French population
185. Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity